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Abstract
Background: Eosinophilic gastritis is related to eosinophilic gastroenteritis, varying only in regards
to the extent of disease and small bowel involvement. Common symptoms reported are similar to
our patient's including: abdominal pain, epigastric pain, anorexia, bloating, weight loss, diarrhea,
ankle edema, dysphagia, melaena and postprandial nausea and vomiting. Microscopic features of
eosinophilic infiltration usually occur in the lamina propria or submucosa with perivascular
aggregates. The disease is likely mediated by eosinophils activated by various cytokines and
chemokines. Therapy centers around the use of immunosuppressive agents and dietary therapy if
food allergy is a factor.
Case presentation: The patient is a 31 year old Caucasian female with a past medical history
significant for ulcerative colitis. She presented with recurrent bouts of vomiting, abdominal pain and
chest discomfort of 11 months duration. The bouts of vomiting had been reoccurring every 7–10
days, with each episode lasting for 1–3 days. This was associated with extreme weakness and
cachexia. Gastric biopsies revealed intense eosinophilic infiltration. The patient responded to
glucocorticoids and azathioprine. The differential diagnosis and molecular pathogenesis of
eosinophilic gastritis as well as the molecular effects of glucocorticoids in eosinophilic disorders are
discussed.
Conclusions: The patient responded to a combination of glucocorticosteroids and azathioprine
with decreased eosinophilia and symptoms. It is likely that eosinophil-active cytokines such as
interleukin-3 (IL-3), granulocyte macrophage colony stimulating factor (GM-CSF) and IL-5 play
pivotal roles in this disease. Chemokines such as eotaxin may be involved in eosinophil recruitment.
These mediators are downregulated or inhibited by the use of immunosuppressive medications.
Background
Eosinophilic gastritis is a serious disease manifesting with
eosinophilia of the blood and stomach with vomiting,
diarrhea, melena, weight loss and/or cachexia. Although
the cause is mostly unknown, food hypersensitivity has
been blamed in several cases. The disease causes edema
and thickening of the bowel which may cause stenosis of
the lumen in some cases. Ascites and local lymphadenop-
athy may be present. Microscopic examination reveals
lamina propria and submucosal infiltration of eosi-
nophils. Treatment usually consist of glucocorticoid ther-
apy although leukotriene modifier drugs are showing
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effectiveness at preventing eosinophil chemotaxis. This
report describes a patient with eosinophilic gastritis and
discusses the disease and the differential diagnosis along
with treatment options.
Case presentation
The patient is a 31 year old Caucasian female with a past
medical history significant for ulcerative colitis. She pre-
sented with recurrent bouts of vomiting, abdominal pain
and chest discomfort. For the past 11 months, bouts of
vomiting had been reoccurring every 7–10 days, with each
episode lasting 1 to 3 days. This was associated with
extreme weakness and cachexia. The patient had kept a
food diary and was unable to associate the symptoms with
any particular food. The episodes were not related to activ-
ity and occurred both at work and home. At the time of
presentation the patient reported considerable social
stress.
The patient also had a history of ulcerative colitis, which
was originally diagnosed 3 years prior to presentation. She
had previously been prescribed 6-mercaptopurine (50 mg
daily) and at time of evaluation was using mesalamine
(400 mg thrice daily). She however continued to experi-
ence diarrhea with occasional blood streaking. Since diag-
nosis there had been a 6.8 kg (15 lbs) weight loss, night
sweats, swelling of her hands and feet, hyperventilation,
generalized weakness, and chest discomfort. In the
months leading up to presentation she was treated with
Doxycycline (100 mg po BID) for facial acne. The doxycy-
cline was soon discontinued due to worsening diarrhea
with no improvement of her symptoms. Though the
patient was under some stress, it was felt that this did not
contribute to her symptoms. She had no history of drug or
alcohol abuse and hence a toxicology screen was not
performed.
On examination, the patient had a height of 165 cm (5'
6"), a weight of 52.7 kg (116 lbs), and a blood pressure of
110/70 mm Hg. She was a thin built young woman. The
head and neck exam was essentially unremarkable with a
fundoscopic exam that showed no evidence of retinitis.
Tympanic membranes were clear bilaterally, turbinates
non-swollen without polyps or discharge. Oral pharynx
was clear. Lymphadenopathy or thyroidmegaly could not
be appreciated. Lung examination was clear to ausculta-
tion. Abdomen was soft with positive bowel sounds, no
hepatosplenomegaly, masses or tenderness noted.
Extremities did not display clubbing, cyanosis, edema, or
joint deformity or tenderness. No eruption was present
and neurological exam was grossly intact. The patient gave
written consent for publication of this report. Her stool
hemoccult test was negative for blood.
Laboratory evaluation
At the time of presentation a complete blood count
showed hemoglobin of 12.6 g/dl, hematocrit of 37.5%,
and WBC of 8,300 cells/mm3 with 16% eosinophils on
peripheral smear. Electrolytes and liver and renal func-
tions were all normal. With further investigation dimin-
ished levels of immunoglobulin G, total protein and
albumin were noted. The total IgG was 341 mg/dl (nor-
mal 613–1295 mg/dl), total protein was 5.0 g/dl (normal
6–8 g/dl) and albumin 3.1 g/dl (normal 3.2–5.0 g/dl).
Pnemococcal vaccination responses were normal suggest-
ing that the IgG deficiency did not result in a functional
antibody defect as would be seen in common variable
immune deficiency. The serum C3, C4, CH-50, and C-1
esterase were within normal limits. Serum amylase and
lipase levels were in the normal ranges. Urine analysis
showed no proteinuria or active sediment. The following
tests were either negative or normal: ESR, ANA, anti-Ro,
anti-La, SCL-70, rheumatoid factor, p-ANCA, and anti-
myeloperoxidase antibodies. Stool studies and serum
serology are listed in Table 1. Allergy skin testing was neg-
ative for a panel of commonly eaten foods. Given the gas-
trointestinal symptoms, an upper GI series was also
carried out. It showed evidence of a small hiatal hernia
and reflux. Echocardiogram showed no evidence of systo-
lic dysfunction or restrictive cardiomyopathy, a feature of
some hypereosinophilic syndromes. Pulmonary function
tests displayed a minimal obstructive lung defect with
normal diffusion capacity. Computerized tomography of
the head (carried out because of the vomiting) was nega-
tive for space occupying lesions.
Table 1: Patient laboratory results
TEST RESULT
Strongyloides antibody negative
Toxocara antibody negative
Trichinella antibody negative
Giardia antibody negative
HIV test negative
Pneumococcal vaccine response normal
Stool ova and parasites negativeClinical and Molecular Allergy 2004, 2 http://www.clinicalmolecularallergy.com/content/2/1/7
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Question 1
Based on the initial history, physical examination and lab-
oratory results, what would be the differential diagnosis in
this 31 year old white female with cyclical vomiting,
weight loss, and peripheral eosinophilia?
a. Parasitic infection
b. Food allergy and atopy
c. Connective tissue disease with vasculitis
d. Idiopathic hypereosinophilic syndrome
e. Adrenal insufficiency
f. Eosinophilic gastritis
Differential diagnosis
Parasitic infestation
Infection with helminithic parasites elicits eosinophilia
by stimulation of Th2 cytokines, especially IL-5. Common
intestinal parasites include Strongyloides stercoralis, hook-
worm, and Toxocara  species [1-5]. Of these parasites,
strongyloidiasis is seen endemically in East Tennessee [2].
S. stercoralis adult worms reproduce parthogenetically in
the gastrointestinal tract. Rhabditiform larvae may
develop into infective filarial forms in the gastrointestinal
tract and also after passage in the feces. Strongyloides can
persist for decades without causing major symptoms. In
many cases, larval and worm penetration of the small
bowel can cause an enteritis associated with eosinophilic
and mononuclear infiltration of the mucosa. Pathologi-
cally, edema, ulceration, and hemmorrhage can be seen in
these patients. Clinically, abdominal bloating, epigastric
pain, and diarrhea can be presenting features in these
individuals. Hematochezia and/or melena occurs in the
minority of these patients (<20%). Filariform larvae can
penetrate the gut and disemminate, especially in patients
who are immunosuppressed or treated with glucocorti-
coids. This condition, referred to as strongyloides hyperin-
fection, is heralded by dyspnea, cough, wheezing, and
hemoptysis [2]. Fever, tachypnea, hypoxemia, and gram
negative meningitis may develop in the sicker patients.
Serology can be used to detect strongyloides if fecal or
sputum examination does not demonstrate the parasite
[2]. In our patient, the absence of parasites in stool and
the lack of serological evidence of strongyloidiasis miti-
gated against this diagnosis.
Food allergy and atopy
Food allergic reactions can present with eosinophilia,
vomiting, and diarrhea [6-9]. Usually, when severe, food
allergy is accompanied by urticaria, angioedema, and/or
symptoms of systemic anaphylaxis. Food allergy must be
differentiated from food intolerance (such as lactose
intolerance) where bloating and diarrhea may occur but
no demonstrable IgE antibody to food protein is discov-
ered. In many cases, foods can induce allergic gastroen-
teritis with findings identical to that seen in our patient
[10]. Some infants may also demonstrate hypersensitivity
to food protein resulting in an enterocolitis [11,12]. Food
allergy may occur in as many as 6% of young children and
up to 2% of the adult population. Common foods known
to elicit reactions in such individuals include milk, wheat,
egg, soy, fish, shrimp, and nuts [9]. The diagnosis is estab-
lished either by skin or by RAST testing [7,9]. Confirma-
tion sometimes requires a double blinded, placebo
controlled challenge. In our patient, the normal IgE levels
and absence of significant sensitivity to foods on skin test-
ing mitigated against the possibility of food allergy. There
have been cases of allergic gastroenteritis where elimina-
tion of suspected foods in the patient leads to disease
amelioration. In our patient, a food elimination diet (that
she had pursued herself) did not alter her clinical course.
The patient refused to attempt an elemental amino acid
diet due to presumed intolerance and costs associated
with these preparations, although this was discussed with
her as a therapeutic option.
Eosinophilic vasculitides (Churg-Strauss syndrome)
Churg-Strauss syndrome (CSS) is a small and medium
sized artery inflammation [2,13]. It frequently involves
the skin, peripheral nerves and lungs with associated
peripheral eosinophilia. The syndrome is characterized by
a triad of 1) asthma, 2) hypereosinophilia, and 3) necro-
tizing vasculitis. There may be three phases of the disease
process. It is possible to have a prodromal period which
may last for years. Normally it consists of allergic rhinitis,
polyposis and asthma. The second phase includes periph-
eral blood and tissue eosinophilia with multisystem
involvement. The third phase is systemic vasculitis with
neuropathy, cardiac disease, and renal disease manifest-
ing. All three phases may present simultaneously. It is
important to note that weight loss and fever may herald
the onset of systemic disease [13]. In some cases, CSS has
been associated with the use of leukotriene modifier drugs
but a causal relationship has not been proven. Chest radi-
ograph is abnormal in approximately half the cases.
Changes range from patchy shifting infiltrates (Loffler's
syndrome) to massive bilateral nodular infiltrates without
cavitations and diffuse interstitial lung disease. Cutaneous
lesions occur over pressure areas, petechiae, purpura, and
peripheral neuropathy is found in the majority of
patients. Cardiac involvement may result in congestive
heart failure. Gastrointestinal involvement may some-
times present as bloody diarrhea or simulating ulcerative
colitis and is caused by bowel ischemia. The patients with
CSS often have pulmonary infiltration, neuropathy,Clinical and Molecular Allergy 2004, 2 http://www.clinicalmolecularallergy.com/content/2/1/7
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hematuria, and elevated ESR with a restrictive cardiomy-
opathy, none of which were features seen in our patient.
Idiopathic hypereosinophilc syndrome
IHES is an idiopathic condition which belongs to the
myeloproliferative disorders group and is associated with
marked peripheral eosinophilia and involvement of mul-
tiple organs such as the heart, gastrointestinal tract, lungs,
brain, and kidneys [14,15]. There are no specific tests
diagnostic of hypereosinophilic syndrome and it remains
a clinical diagnosis and essentially a diagnosis of exclu-
sion. A definition of the syndrome has been proposed
with 3 defining features:
1) blood eosinophilia >1500 esoinophils/mm3 present
for more than 6 months
2) no other apparent etiologies for eosinophilia such as
parasitic infection, malignancy, vasculitis, drug hypersen-
sitivity or atopic disease
3) signs and symptoms of end organ dysfunction includ-
ing cardiac disease, neuropathy, and hepatic dysfunction
Hypereosinophilic syndrome occurs predominantly in
males between the ages of 20–50. Onset is usually insidi-
ous and eosinophilia is detected incidentally [14-16].
Hematological, cardiac, cutaneous, neurological, pulmo-
nary, hepatic, or gastrointestiunal symptoms may pre-
dominate presentation. Myalgia, diarrhea, psychiatric
disturbances, and ocular disease have also been described.
Elevated serum IgE, elevated levels of tumor necrosis fac-
tor (TNF-α) and interleukin-5 (IL-5) [17], polyclonal
hyperglobulinemia, and good response to steroids are
additional diagnostic features of this disease. Our patient
had no evidence of multiple organ involvement and no
evidence of cardiac, hepatic or renal disease excluding this
diagnosis.
Adrenal insufficiency
The loss of endogenous glucocorticoids, regardless of the
cause, results in eosinophilia. The etiology could include
a primary failure due to autoimmune adrenalitis, or sec-
ondary failure arising from many conditions such as infec-
tion, neoplasia, and granulomatous/infiltrative disorders
[18]. Though the disease itself is rare, its presentation may
be cryptic and the diagnosis missed. It is also important to
realize that patients who have been treated with exoge-
nous courses of glucocorticoids for various inflammatory
conditions may be more prone to developing adrenal fail-
ure, especially in stressful conditions such as surgery. Lab-
oratory evaluation is likely to demonstrate hyperkalemia
and hypoglycemia. Clinically, weight loss, anorexia, and
vomiting with eosinophilia may be seen [18]. It has been
suggested that the presence of relative eosinophilia in crit-
ically ill patients is associated with clinical signs of relative
adrenal insufficiency [19,20]. Our patient had no obvious
evidence of adrenal insufficiency and the tests for her cor-
tisol axis were within normal limits, excluding this
diagnosis.
Eosinophilic gastritis
This is a pathological diagnosis characterized by periph-
eral eosinophilia, eosinophilic infiltration of the bowel
wall, and gastrointestinal symptoms. It affects all age
groups, predominately in the second to sixth decades of
life. The disease affects both sexes with a slightly increased
prevalence in males. The cause is largely unknown. An
allergic or immunological reaction to food antigen seems
likely in 20–50% of cases. In the case of eosinophilic gas-
tritis, there is mainly invasion of the gastric mucosa while
in eosinophilic gastroenteritis, both the stomach and
small intestine may be involved. These disorders are fur-
ther reviewed in the sections below.
Question 2
What diagnostic test will you perform in this patient to
confirm the diagnosis?
a. blood culture
b. gastric biopsy
c. stool alpha 1 antitrypsin
d. ESR
e. Bone marrow biopsy
The patient underwent esophagogastroduodenoscopy
(EGD) and had multiple gastric biopsies taken by a con-
sultant gastroenterologist. Images revealed multiple ero-
sions in the gastric and duodenal mucosa and Barrett's
esophagitis (Figure 1A and 1B). Gastric biopsy showed
eosinophilic infiltration of the mucosa in clusters, a diag-
nostic feature of eosinophilic gastritis (Figure 1C and 1D).
Duodenal and ileal biopsies demonstrated no eosi-
nophilic infiltration. Viral inclusions were absent on
biopsy tissue and no evidence of celiac disease was
present. Follow up colonoscopy revealed some colitis
involving the rectosigmoid colon, with neutrophilic infil-
tration but no crypt abscesses. Cecal, right colon and ileal
biopsies were normal and these findings were improved
from prior studies.
Diagnosis: Eosinophilic gastritis with protein losing enteropathy
The diagnosis of eosinophilic gastritis was most compati-
ble with the presentation of our patient. Her history of
nausea and vomiting associated with weight loss and
lower extremity edema are recognized features of theClinical and Molecular Allergy 2004, 2 http://www.clinicalmolecularallergy.com/content/2/1/7
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disease. Although cyclical vomiting has not been
described as a typical feature of eosinophilic gastritis, this
was the presenting feature in our patient. Initially some of
these symptoms could have been contributed to her ulcer-
ative colitis which can also be associated with eosi-
nophilic infiltration but not to the degree and severity
seen in this patient. The peripheral edema was most likely
secondary to the protein losing enteropathy, hypoalbu-
minemia, and cachexia (Figure 2).
Eosinophilic gastritis is a disease that affects both sexes
with a slightly increased prevalence in males. Eosinophilic
gastritis is a rare disease with less than 300 cases previ-
ously reported. The disease has been predominantly
described in Caucasians [21,22] with some reported cases
in Asians [23,24]. Eosinophilic gastritis is related to eosi-
nophilic gastroenteritis, varying only in regards to the
extent of disease and small bowel involvement. Common
symptoms reported are similar to our patient's and
include: abdominal pain, epigastric pain, anorexia, bloat-
ing, weight loss, diarrhea, ankle edema, dysphagia,
melena, and postprandial nausea and vomiting. Given a
somewhat non-specific presentation, a high index of sus-
picion must be maintained once peripheral eosinophilia
is noted. If a patient has concomitant ascites the ascitic
fluid will have a high eosinophilia count. In some cases,
presentations have been diverse and cryptic such as
patients who present with a solitary gastric ulcer or pyloric
outlet obstruction and those who present like gastric
malignancy [23-26]. In some cases, parasitic diseases such
Esophagogastroduodenoscopy showing gastric erosion (A) and esophogitis (B) Figure 1
Esophagogastroduodenoscopy showing gastric erosion (A) and esophogitis (B). Panels C and D show eosinophil infiltration of 
gastric biopsy samples.Clinical and Molecular Allergy 2004, 2 http://www.clinicalmolecularallergy.com/content/2/1/7
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as anisakiasis have mimicked eosinophilic gastritis [27].
Stefanini et al. reported on the paraneoplastic association
of eosinophilic gastroenteritis with a large cell carcinoma
of the lung [28]. Some cases have been linked to the use
of medications such as gemfibrozil [29]. In many cases, an
etiology is not readily discernable.
Three types of eosinophilic gastroenteritis have been pro-
posed linking the clinical manifestations and depth of the
disease process [30].
Type I – predominantly mucosal and characterized by
fecal blood loss, iron deficiency anemia, protein losing
enteroropathy, and malabsorption. Patients normally
present with colicky abdominal pain, nausea, vomiting,
diarrhea, and weight loss. A history of atopy is common
in up to half of patients.
Type II – a muscle layer disease with obstructive symp-
toms due to thickening and rigidity of the GI tract. Eosi-
nophilic involvement in the majority of cases is localized
to the stomach but can involve the small bowel. The his-
tory of atopy is much less common.
Type III – shows predominantly subserosal disease with
eosinophilic ascites. This is the least common cause of the
Pathology of eosinophilic gastritis Figure 2
Pathology of eosinophilic gastritis. In the presence of an inciting event, inflammatory cells like T-cells and mast cells are acti-
vated to produce a host of eosinophilic cytokines that regulate eosinophil biology, activation, recruitment, and survival. Once in 
the gastric mucosa, eosinophils can orchestrate tissue damage by releasing toxic proteins like eosinophil cationic protein, 
major basic protein, eosinophil peroxidase, and eosinophil derived neurotoxin. With mucosal injury, vomiting, diarrhea, 
cachexia, and peripheral edema ensue.Clinical and Molecular Allergy 2004, 2 http://www.clinicalmolecularallergy.com/content/2/1/7
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disease. The entire GI wall is involved. The ascitic fluid is
noted to have a high eosinophil count. A history of aller-
gic reactions is common, and more than one site may be
involved with a mixed clinical manifestation [16,30]
Pathologically the macroscopic portion of the bowel is
thickened and swollen with varying degrees of induration,
edema, hyperemia and nodularity. These changes can lead
to obstruction of the lumen. Regional lymphadenopathy
and ascites may be present. Microscopic features of eosi-
nophilic infiltration usually occur in the lamina propria
or submucosa with a tendency to see perivascular aggrega-
tion of eosinophils as seen in our patient [16,30].
Pathogenesis and role of cytokines in eosinophilic gastritis
Figure 2 demonstrates presumed pathways that could lead
to the development of eosinophilic gastritis. Inciting
events such as food allergens can trigger T cell and mast
cell activation, and in the case of allergen, immunoglobu-
lin E (IgE) is involved in mast cell degranulation. This
leads to the elaboration of hematopoietic cytokines such
as IL-5 and pluripotential cytokines such as IL-3 and GM-
CSF that modulate bone marrow production of eosi-
nophils. Eosinophilia in the blood stream is followed by
eosinophil recruitment into tissue involving endothelial
cell adhesion molecules and transendothelial migration
of the eosinophil into tissue. Cytokines such as IL-4 and
IL-13 as well as IL-1 beta and TNF-α are involved in induc-
tion of cell adhesion molecules leading to selective eosi-
nophil recruitment. IL-4 can induce vascular cell adhesion
molecule (VCAM)-1 on endothelial surfaces while IL-1
and TNF-α can induce intercellular adhesion molecule
(ICAM)-1 expression. These bind corresponding ligands
VLA-4 and LFA-1 respectively on eosinophils that leads to
adhesion and transendothelial migration. Tissue level
activation and survival of eosinophils are regulated by
cytokines such as IL-5 and GM-CSF, some expressed by
the eosinophil itself in an autocrine manner [31,32].
Recruitment of eosinophils to tissue and their accumula-
tion there could be regulated by eotaxin in association
with IL-5 [33-36]. Eotaxin mediates some of its biological
effects by binding to the receptor CCR3 on the eosinophil.
Eosinophil infiltration is accompanied by degranulation
and the release of a plethora of mediators, including
cytokines, chemokines, major basic protein, eosinophilic
cationic protein and lipid mediators, further accentuating
the damage to gastric tissue [37]. Desreumaux and cow-
orkers detected IL-3, IL-5 and GM-CSF in the duodenal
and colonic tissue in 90% of patients with eosinophilic
gastroenteritis [38]. Investigators have demonstrated
some of these cytokines in vivo in humans affected by
eosinophilic gastritis. Jaffe JS et al. showed enhanced
expression of IL-4, IL-5, and interferon gamma in the
peripheral T cells of patients with allergic eosinophilic
gastroenteritis [39]. The importance of eotaxin in eosi-
nophilic gastroenteritis was shown by Hogan et al [40].
These investigators used an animal model of food aller-
gen-induced eosinophilic gasroenetritis and demon-
strated that in the absence of eotaxin, eosinophil
accumulation in the gut was ablated in spite of eosi-
nophilia in the peripheral blood. Thus critical roles have
been assigned to IL-5, GM-CSF, and eotaxin in eosinophil
accumulation in eosinophilic gastroenteritis. A list of
proinflammatory cytokines that mediate eosinophil
migration, activation, and survival as related to eosi-
nophilia are listed in Table 2.
Management of eosinophilic gastritis
There have been no prospective, randomized clinical trials
reported in the current body of literature. This has led to
empiric treatment, modified to the severity of the disease.
The possible strategies for treatment are summarized in
Table 3. Treatment with an elimination diet based on the
results of skin prick and RAST testing can be done. In
Table 2: Cytokines regulating eosinophilia
Cytokine Family Effect on Eosinophils Other Relevant Functions
TNF-α [59,60]   Monokine CAM expression, recruitment Vascular permeability increase, eosinophil degranulation
IL-1β [59,60]  Monokine CAM expression, eosinophil recruitment Eosinophil activation, eosinophil degranulation
IL-3 [59]  HP survival, differentiation Multipotential HP
IL-4   [59,60]  Th2 VCAM expression on EC IgE synthesis
IL-5 [59]  Th2 Hematopoiesis, activation, survival, mediator IgA synthesis
IL-13 [59,60]  Th2 VCAM expression on EC IgE synthesis, Mucus production
GM-CSF [59,60]  Th1/2 Activation MO activation, hematopoiesis
SCF [59]  HP Adhesion Mast cell growth
Eotaxins [59]  Chemokine Chemoattractant Multipotential HP
MCPs [59,60]  Chemokine Chemoattractant MO chemotaxis
RANTES [59,60]  Chemokine Chemoattractant Histamine release from basophils
CAM, Cell Adhesion Molecule; EC, endothelial cells; CSF, Colony Stimulating Factor; Th2, type 2 T helper cell; HP, hematopoietin; APR, acute 
phase response, MO, Monocyte-macrophage lineage cells; VCAM-vascular cell adhesion molecule; MCP-monocyte chemoattractant protein-1Clinical and Molecular Allergy 2004, 2 http://www.clinicalmolecularallergy.com/content/2/1/7
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severe cases, an elemental amino acid diet may need to be
instituted [41,42]. However, a causative agent is fre-
quently not evident.
Steroids have been successfully used in patients who fail
elimination diet. Dosage is normally 20–40 mg of pred-
nisone daily. Improvement usually occurs within two
weeks of beginning therapy and the dose of steroids need
to be rapidly tapered after remission. Relapses are com-
mon and some patients require continuous low dose ster-
oids to control symptoms. In such cases, especially those
who do not tolerate the complications of steroids, alterna-
tive strategies, such as in our patient, may be attempted.
Glucocorticoids, the most effective agents for reducing
eosinophilia, suppress the gene transcription of IL-3, IL-4,
IL-5, GM-CSF, and various chemokines [1]. In many stud-
ies it has been proven that glucocorticoids can decrease
both the number of eosinophils and the effects of their
toxic products. After short term treatment with glucocorti-
coids a significant decrease in the levels of serum eosi-
nophil cationic protein (ECP) and serum eosinophil
peroxidase was observed [43]. Evidence supports that
decreased level of serum ECP may serve as an objective
indicator for the clinical activity and treatment of allergic
asthmatics [44]. It has been shown that dexamethasone
prevents antigen-induced hyperactivity by protecting neu-
ronal M (2) muscarinic receptors from antagonism by
eosinophil major basic protein. This protective
mechanism appears to be specifically inhibiting eosi-
nophil recruitment to the airway nerves [45]. Treatment
with high dose methylprednisolone results in significant
reduction in peripheral blood eosinophils and pheno-
typic changes characterized by decreased expression of
CD11b, CD18, and CD13 which have an important role
in the action of eosinophils [46]. In addition, glucocorti-
coids inhibit the cytokine-dependent survival of
eosinophils [47]. Treatment with systemic or topical
(inhaled or intranasal) glucocorticoids causes a rapid
reduction in eosinophils. It is important to note that a few
patients have a resistance to glucocorticoid therapy and
maintain eosinophilia despite high doses of steroids [48].
Patients with glucocorticoid resistance sometimes require
alternative approaches.
Our patient failed use of oral cromolyn sodium (gastro-
crom®) and montelukast sodium (10 mg/day), and con-
tinued to require frequent pulses of glucocrticoids in spite
of the coadministration of these medications. This
prompted us to use alternative agents. The use of ketotifen
and hydroxyurea have been reported to have some success
in a limited number of cases. Van Dellen and colleagues
reported on the succesful use of oral cromoyln in a 47 year
old patient with documented food allergy and eosi-
nophilic gastritis [49]. Ketotifen, an H1 class antihista-
mine, was used as an alternative in 6 patients with
eosinophilic gastroenteritis [50]. Patients treated with
ketotifen showed eosinophilic clearing in follow up biop-
sies with associated weight gain. Montelukast has also
been used as a steroid sparing therapy. One case report
displayed successful steroid tapering of a steroid depend-
ent patient with eosinophilic gastroenteritis once monte-
lukast was begun [51]. Daikh et al. commented on the
reduction of eosinophilia with montelukast but the
absence of any symptomatic relief in a patient with eosi-
nophilic gastroenteritis [52]. However, Schwartz and cow-
orkers succesfully managed to wean a patient with
eosinophilic gastroenetritis off glucocorticoids suggesting
variable responses to this drug as seen in diseases such as
asthma [53]. Given the benign quality of montelukast,
this drug may be tried in eosinophilic gastroenetritis and
continued therapy based on response rates. Our patient
had no response to montelukast and vomiting continued
Table 3: Treatment strategies for eosinophilic gastritis
Strategy Intervention Comments
Diet elimination, food avoidance, elemental amino acid 
diet, total parenteral alimentation
allergic patient
allergic patient poor tolerance and cost only in severe patient
Antihelminthics mebendazole, others emperic trial, endemic areas
Mast cell stabilizer cromoglycate sodium allergic patient, anecdotal cases, administer QID, therapeutic trial
Glucocorticoids prednisone or equivalent lowest dose, taper, alternate day therapy, many adverse effects
Montelukast tablet given once/day leukotriene blocker, only anecdotal evidence
Ketotifen available in Canada investigational
Azathioprine immunosupressive bone marrow suppression
Others cyclophosphamide, hydroxyurea, cyclosporine A investigational
investigational
investigational
Biologicals antibody to IL-5, antibody to CCR3, antibody to IgE investigational
investigational
investigational (Food allergy)
Antibiotics ciprofloxacin, metronidazole for malabsorption bacterial overgrowthClinical and Molecular Allergy 2004, 2 http://www.clinicalmolecularallergy.com/content/2/1/7
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unabated unless treated with glucocorticoids. Suplatast
tosilate has also been reported as a successful treatment
but is not currently available in the United States. There
are also ongoing pilot studies investigating anti-IL-5 ther-
apy. It is unknown whether these newer biological agents
such as antibody to IL-4, IL-5, or CCR3 may have a bene-
ficial effect on the course of eosinophilic gastroenteritis. It
is likely in the food allergic individual, antibody to IgE
may have some beneficial therapeutic effects. Alternatives
in patients who are dependent on steroids or resistant to
them include myelosuppressive drugs such as hydroxyu-
rea, azathioprine, vincristine, methotrexate, or interferon
alpha. Interferon alpha seem to be especially promising,
and this is mostly due to its inhibitory effect on the
degranulation of eosinophils or on the expression of eosi-
nophilic active cytokines by T cells and mast cells as
described by us [54,55].
Our patient was started on prednisone (40 mg po once
daily). Also at that time she was started on a proton pump
inhibitor (lansoprazole 30 mg daily) for esophageal reflux
which greatly improved her reflux symptomatology. Pred-
nisone induced a dramatic remission in her symptoms
and induced a feeling of well being. There was reversal of
the protein losing enteropathy as well as improvements in
eosinophilia and serum levels of total protein and albu-
min. The cyclical vomiting episodes were aborted (one
such cycle is shown in Figure 3. On prednisone, these
Remission of Nausea and Vomiting with Prednisone Figure 3
Remission of Nausea and Vomiting with Prednisone. One cycle shown. Nausea was graded by patient from 0 (absent) to 10 
(constant/severe). "P" indicates where prednisone was initiated. Prednisone dose is provided in mg/day in parenthesis on x-
axis. After prednisone was initiated and maintained at 10–20 mg/day, the patients cyclical vomiting was aborted for the next 2 
years of follow up. Body weight, total protein, and albumin levels improved, while eosinophilia was absent.Clinical and Molecular Allergy 2004, 2 http://www.clinicalmolecularallergy.com/content/2/1/7
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cycles were completely abolished in the subsequent
months). However, given the severe adverse effects of ster-
oids including mood swings and weight gain, the patient
opted for alternative therapies. She was started on azathi-
oprine (Imuran®) at 50 mg/day and was quickly able to
taper down to a maintainence dose of prednisone of 2
mg/day. She has remained on azathioprine for over 1 year
with excellent benefits. It is likely that the combination of
prednisone and azathiprine was more effective in this
patient than either alone or 6-mercaptopurine. While it
was likely that mescalamnine induced an allergic reaction
or in when administered concomitantly with 6-mercap-
topurine, induced toxic side effects, the discontinuation of
mescalamine had no beneficial effects on the eosinophilia
or vomiting in this patient [56,57]. It is likely that the
patient may have had a very low activity of thiopurine
methyltransferase (TPMT) but this was not measured in
the patient at the time of the study [58].
Conclusions
The patient responded to a combination of glucocorticos-
teroids and azathioprine with decreased eosinophilia and
symptoms. It is likely that eosinophil-active cytokines
such as interleukin-3 (IL-3), granulocyte macrophage col-
ony stimulating factor (GM-CSF) and IL-5 play pivotal
roles in this disease. Chemokines such as eotaxin may be
involved in eosinophil recruitment. These mediators are
downregulated or inhibited by the use of immunosup-
pressive medications.
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